Figure 1.
NOTA and DOTA conjugation of TRC105.
Figure 2.
Flow cytometry analysis of TRC105 and NOTA-TRC105 in HUVECs (CD105-positive) and MCF-7 (CD105-negative) cells at different concentrations.
Figure 3.
Small animal PET imaging of 4T1 tumor-bearing mice.
A. Serial coronal PET images at 4, 24, and 48 h post-injection of 64Cu-NOTA-TRC105. Tumors are indicated by arrowheads. B. Time-activity curves of tumor, liver, blood, and muscle after intravenous injection of 64Cu-NOTA-TRC105 into 4T1 tumor-bearing mice (n = 3) C. Representative PET/CT images of 64Cu-NOTA-TRC105 in 4T1 tumor-bearing mice at 48 h post-injection. D. Comparison of the 4T1 tumor uptake of 64Cu-NOTA-TRC105 and 64Cu-DOTA-TRC105. *: P<0.05.
Figure 4.
Biodistribution studies in 4T1 tumor-bearing mice.
A. Biodistribution of 64Cu-NOTA-TRC105 and 64Cu-DOTA-TRC105 at 24 h post-injection (n = 3). B. Biodistribution of 64Cu-NOTA-TRC105 and 64Cu-DOTA-TRC105 at 48 h post-injection (n = 3). *: P<0.05.